Literature DB >> 18679420

Atm heterozygosity does not increase tumor susceptibility to ionizing radiation alone or in a p53 heterozygous background.

J H Mao1, D Wu, R DelRosario, A Castellanos, A Balmain, J Perez-Losada.   

Abstract

Ataxia-Telangiectasia (A-T) is an autosomal recessive human disease characterized by genetic instability, radiosensitivity, immunodeficiency and cancer predisposition, because of mutation in both alleles of the ATM (ataxia-telangiectasia mutated) gene. The role of Atm heterozygosity in cancer susceptibility is controversial, in both human and mouse. Earlier studies identified deletions near the Atm gene on mouse chromosome 9 in radiation-induced lymphomas from p53 heterozygous mice. To determine whether Atm was the target of these deletions, Atm heterozygous as well as Atm/P53 double heterozygous mice were treated with ionizing radiation. There were no significant differences in tumor latency, progression and lifespan after gamma-radiation in Atm heterozygous mice compared with their wild-type control counterparts. Deletions were found on chromosome 9 near the Atm locus in radiation-induced tumors, but in 50% of the cases the deletion included the knockout allele, and the expression of Atm was maintained in the tumors indicating that loss of heterozygosity on chromosome 9 is not driven by Atm, but by an alternative tumor suppressor gene located near Atm on this chromosome. We conclude that Atm heterozygosity does not confer an increase in tumor susceptibility in this context.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18679420     DOI: 10.1038/onc.2008.280

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  Atm-deficient mice exhibit increased sensitivity to dextran sulfate sodium-induced colitis characterized by elevated DNA damage and persistent immune activation.

Authors:  Aya M Westbrook; Robert H Schiestl
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

2.  Chromatin protein L3MBTL1 is dispensable for development and tumor suppression in mice.

Authors:  Jinzhong Qin; Denille Van Buren; Hsien-Sung Huang; Lei Zhong; Raul Mostoslavsky; Schahram Akbarian; Hanno Hock
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

Review 3.  ATM mutations for surgeons.

Authors:  Sara A Mansfield; Robert Pilarski; Doreen M Agnese
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

Review 4.  Genomic Biomarkers for Breast Cancer Risk.

Authors:  Michael F Walsh; Katherine L Nathanson; Fergus J Couch; Kenneth Offit
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 5.  Targeting the ATM Kinase to Enhance the Efficacy of Radiotherapy and Outcomes for Cancer Patients.

Authors:  María E Guerra García; David G Kirsch; Zachary J Reitman
Journal:  Semin Radiat Oncol       Date:  2022-01       Impact factor: 5.934

6.  Mutational Analysis of Ionizing Radiation Induced Neoplasms.

Authors:  Amy L Sherborne; Philip R Davidson; Katharine Yu; Alice O Nakamura; Mamunur Rashid; Jean L Nakamura
Journal:  Cell Rep       Date:  2015-09-03       Impact factor: 9.423

7.  Loss of p53 Ser18 and Atm results in embryonic lethality without cooperation in tumorigenesis.

Authors:  Heather L Armata; Punita Shroff; David E Garlick; Krista Penta; Andrew R Tapper; Hayla K Sluss
Journal:  PLoS One       Date:  2011-09-27       Impact factor: 3.240

8.  A bioinformatics filtering strategy for identifying radiation response biomarker candidates.

Authors:  Jung Hun Oh; Harry P Wong; Xiaowei Wang; Joseph O Deasy
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

9.  Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk.

Authors:  Steve Braunstein; Jean L Nakamura
Journal:  Front Oncol       Date:  2013-04-03       Impact factor: 6.244

Review 10.  Inflammation, a significant player of Ataxia-Telangiectasia pathogenesis?

Authors:  Majid Zaki-Dizaji; Seyed Mohammad Akrami; Gholamreza Azizi; Hassan Abolhassani; Asghar Aghamohammadi
Journal:  Inflamm Res       Date:  2018-03-26       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.